Baseline characteristics of the whole study population
| . | All . | End of treatment . | Intercalated . | P . |
|---|---|---|---|---|
| n = 1384 (%) . | n = 635 (%) . | n = 749 (%) . | ||
| Age (y), median (range) | 62.5 (17-88) | 63.0 (18-86) | 62.0 (17-88) | .065 |
| Follow-up (mo), median (IQR) | 37.9 (21.8-59.6) | 41.0 (25.0-63.2) | 35.2 (19.6-56.5) | |
| Baseline creatinine clearance, median (range) | 98.2 (33.3-345.2) | 94.5 (33.3-345.2) | 101.9 (35.5-332) | .0001 |
| Male sex | 840 (60.7) | 393 (61.9) | 447 (59.7) | .40 |
| Advanced stage | 1156 (83.5) | 509 (80.2) | 647 (86.4) | .0019 |
| Raised LDH baseline | 943 (70.0) | 410 (68.0) | 533 (71.5) | .16 |
| Missing/unknown | 36 | 32 | 4 | |
| ECOG ≥2 | 358 (25.9) | 158 (25.0) | 200 (26.7) | .47 |
| Missing/unknown | 3 | 3 | 0 | |
| Extranodal sites | ||||
| 0-1 | 586 (42.3) | 282 (44.4) | 304 (40.6) | .11* |
| 2 | 421 (30.4) | 191 (30.1) | 230 (30.7) | |
| ≥3 | 377 (27.2) | 162 (25.5) | 215 (28.7) | |
| Renal or adrenal involvement | 240 (17.3) | 102 (16.1) | 138 (18.4) | .25 |
| Testicular involvement | 175 (12.7) | 95 (15.0) | 80 (10.7) | .016 |
| Breast involvement | 56 (4.1) | 18 (2.8) | 38 (5.1) | .037 |
| Double or triple hit | 66 (6.1) | 32 (6.7) | 34 (5.7) | .47 |
| Missing/unknown | 308 | 159 | 149 | |
| CNS IPI | ||||
| Low (0-1) | 203 (14.9) | 107 (17.5) | 96 (12.9) | .083* |
| Intermediate (2-3) | 555 (40.9) | 241 (39.4) | 314 (42.0) | |
| High (4-6) | 600 (44.2) | 263 (43.0) | 337 (45.1) | |
| Missing/unknown | 26 | 24 | 2 | |
| Baseline CNS assessment | 703 (50.8) | 382 (60.2) | 321 (42.9) | <.0001 |
| . | All . | End of treatment . | Intercalated . | P . |
|---|---|---|---|---|
| n = 1384 (%) . | n = 635 (%) . | n = 749 (%) . | ||
| Age (y), median (range) | 62.5 (17-88) | 63.0 (18-86) | 62.0 (17-88) | .065 |
| Follow-up (mo), median (IQR) | 37.9 (21.8-59.6) | 41.0 (25.0-63.2) | 35.2 (19.6-56.5) | |
| Baseline creatinine clearance, median (range) | 98.2 (33.3-345.2) | 94.5 (33.3-345.2) | 101.9 (35.5-332) | .0001 |
| Male sex | 840 (60.7) | 393 (61.9) | 447 (59.7) | .40 |
| Advanced stage | 1156 (83.5) | 509 (80.2) | 647 (86.4) | .0019 |
| Raised LDH baseline | 943 (70.0) | 410 (68.0) | 533 (71.5) | .16 |
| Missing/unknown | 36 | 32 | 4 | |
| ECOG ≥2 | 358 (25.9) | 158 (25.0) | 200 (26.7) | .47 |
| Missing/unknown | 3 | 3 | 0 | |
| Extranodal sites | ||||
| 0-1 | 586 (42.3) | 282 (44.4) | 304 (40.6) | .11* |
| 2 | 421 (30.4) | 191 (30.1) | 230 (30.7) | |
| ≥3 | 377 (27.2) | 162 (25.5) | 215 (28.7) | |
| Renal or adrenal involvement | 240 (17.3) | 102 (16.1) | 138 (18.4) | .25 |
| Testicular involvement | 175 (12.7) | 95 (15.0) | 80 (10.7) | .016 |
| Breast involvement | 56 (4.1) | 18 (2.8) | 38 (5.1) | .037 |
| Double or triple hit | 66 (6.1) | 32 (6.7) | 34 (5.7) | .47 |
| Missing/unknown | 308 | 159 | 149 | |
| CNS IPI | ||||
| Low (0-1) | 203 (14.9) | 107 (17.5) | 96 (12.9) | .083* |
| Intermediate (2-3) | 555 (40.9) | 241 (39.4) | 314 (42.0) | |
| High (4-6) | 600 (44.2) | 263 (43.0) | 337 (45.1) | |
| Missing/unknown | 26 | 24 | 2 | |
| Baseline CNS assessment | 703 (50.8) | 382 (60.2) | 321 (42.9) | <.0001 |
P values are χ2 for discrete variables (*for trend) and Wilcoxon Mann-Whitney for continuous.
CNS IPI, central nervous system international prognostic index; ECOG, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; LDH, lactate dehydrogenase.